Ignite Creation Date:
2024-05-06 @ 7:08 PM
Last Modification Date:
2024-10-26 @ 3:01 PM
Study NCT ID:
NCT05904886
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2023-05-23
Brief Title:
A Study Evaluating Atezolizumab and Bevacizumab With or Without Tiragolumab in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma IMbrave152
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
A Phase III Randomized Double-Blind Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab With or Without Tiragolumab in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SKYSCRAPER-14
Brief Summary:
The purpose of this study is to assess the efficacy and safety of tiragolumab an anti-TIGIT monoclonal antibody when administered in combination with atezolizumab and bevacizumab as first-line treatment in participants with unresectable locally advanced or metastatic hepatocellular carcinoma HCC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-503422-39-00 | REGISTRY | EU CT Number | None |